RxDoctor Payments Data

Kari Smith

Family · Saint Paul, MNNPI 1114935368

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,000 of the $4,777 with a category attached, or 62.8%. Boston Scientific accounts for 91.9% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $3,436, 3.0 times the $1,137 reported in 2023. Among family clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,777in general payments, 2019–2025

Across 28 payments — averaging $170.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Medtronic$162
  • Cvrx, Inc.$63
  • E.r. Squibb & Sons, L.L.C.$60
  • Regeneron Healthcare Solutions, Inc.$21
  • Novartis$17
  • plus $61 from 4 others

What the payments were for

  • Speaking & faculty fees$3,00063%
  • Travel & lodging$89219%
  • Food & beverage$88519%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,777 in reported general payments places this provider in the 95th percentile of 1,121 family providers in Minnesota.

See all family providers in Minnesota

Medicare billing

Part B allowed, 2024
$40,243
Medicare patients
259
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$240,626
XareltoRivaroxaban96$128,860
Dabigatran EtexilateDabigatran Etexilate Mesylate11$5,655
Dofetilide14$4,868
Metoprolol Succinate235$4,545
SotalolSotalol Hcl121$2,635
Flecainide Acetate51$1,555
Diltiazem 24hr Er (Xr)Diltiazem Hcl17$968
Metoprolol Tartrate95$929
Amiodarone Hcl44$822
Diltiazem 24hr Er (Cd)Diltiazem Hcl25$760
Dilt-XrDiltiazem Hcl12$757
Bisoprolol Fumarate29$654
Lisinopril57$630
Diltiazem 24hr ErDiltiazem Hcl12$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$240,626161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,121 family providers in Minnesota.

Other family in Saint Paul

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →